How are energy investors positioned?
Cantor Fitzgerald maintained its overweight rating on Roivant Sciences (NASDAQ:ROIV), a $7.55 billion market cap biotech company, following an investor call focused on the company’s oral TYK2/JAK1 inhibitor brepocitinib in Dermatomyositis (DM). According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet, though current metrics suggest the stock is trading above its Fair Value.
The Phase 3 trial for brepocitinib in DM is expected to report results in the second half of 2025, with Cantor Fitzgerald estimating data will be available by September or October. Roivant Sciences anticipates a potential launch for the treatment in early 2027 if the trial proves successful. Analyst consensus remains bullish, with price targets ranging from $12 to $22 per share. For deeper insights into ROIV’s potential, InvestingPro subscribers can access the comprehensive Pro Research Report, which includes detailed analysis of the company’s pipeline and financial metrics.
Roivant is simultaneously advancing brepocitinib in other indications, with a Phase 3 trial in Non-infectious uveitis (NIU) expected to report results in the first half of 2027. The company also plans to release proof-of-concept data for the drug in cutaneous sarcoidosis in the second half of 2026.
Cantor Fitzgerald expressed strong confidence in brepocitinib’s potential in DM, noting that while JAK inhibitors have shown efficacy in the condition, the primary risk for the trial centers around placebo response on the registrational endpoint of Total (EPA:TTEF) Improvement Score (TIS).
The research firm highlighted new pooled data on forced steroid tapering success and baseline characteristics that should increase confidence that placebo response rates will be in-line with or lower than those observed in the Phase 3 ProDERM study for Octagam, an intravenous immunoglobulin treatment.
In other recent news, Roivant Sciences has been the focus of several investment firms, with both H.C. Wainwright and Guggenheim reiterating their Buy ratings on the company’s stock. H.C. Wainwright maintains an $18.00 price target, highlighting Roivant’s strategic developments, including its involvement with Immunovant (NASDAQ:IMVT) and the expansion of its development focus to include Sjogren’s Disease and cutaneous lupus erythematosus. Guggenheim, with a $15.00 price target, emphasized the potential of brepocitinib in dermatomyositis, noting the drug’s ongoing Phase III VALOR study and its potential to generate significant sales if approved.
Additionally, Pulmovant, a subsidiary of Roivant, announced positive Phase 1 data for mosliciguat, an inhaled treatment for pulmonary hypertension. The study results, published in Clinical Pharmacokinetics, showed the drug was well-tolerated and indicated effective systemic exposure without serious side effects. Roivant Sciences is also undergoing management changes, with Eric Venker taking over as CEO of Immunovant, which aligns with the company’s strategic shift in its development pipeline.
The company is preparing for key data announcements for brepocitinib and mosliciguat, which could impact its future growth. These developments reflect Roivant’s ongoing commitment to expanding its therapeutic areas and managing its business effectively. The firm’s financial health is seen as supportive of its future investment opportunities, according to analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.